Medfinder
Back to blog

Updated: January 18, 2026

Kenalog Shortage Update: What Patients Need to Know in 2026

Author

Peter Daggett

Peter Daggett

Calendar with medication bottle and upward availability trend graph

The Kenalog (triamcinolone acetonide) shortage is ongoing in 2026. Here's the latest update on which manufacturers are affected and what to do.

If you've been prescribed Kenalog (triamcinolone acetonide injection) and your pharmacy can't fill it, you're experiencing the impact of one of the most widespread corticosteroid shortages in recent years. This article provides the most up-to-date information available for patients — including which manufacturers are affected, why the shortage is happening, what it means for your treatment, and what you can do.

Kenalog Shortage Status in 2026: Active

As of 2025–2026, triamcinolone acetonide injectable suspension is listed as an active shortage by the American Society of Health-System Pharmacists (ASHP). The shortage primarily affects the 40 mg/mL injectable formulation, which is the most widely used form. Here's the current status by manufacturer:

Eugia US: Permanently discontinued triamcinolone acetonide 40 mg/mL vials in mid-2025, removing a significant source of generic supply from the market.

Hikma: Has 40 mg/mL 1 mL vials available but only on allocation to contracted customers. Has not provided a reason for the shortage.

Long Grove Pharmaceuticals: 5 mL and 10 mL vials on intermittent back order due to increased demand. Releasing product as it becomes available.

Viatris (Mylan): 5 mL and 10 mL vials on back order. Estimated release date: late-June 2026. Has not provided a reason.

Teva: In shortage. Has not provided a reason.

Amneal: Product on allocation to contracted customers only.

Bristol-Myers Squibb (brand Kenalog): Has not provided a reason for shortage of brand Kenalog injectable suspension; some presentations remain available.

How Did the Kenalog Shortage Start?

The Kenalog shortage reflects broader structural vulnerabilities in the U.S. generic injectable drug market. Sterile injectable medications like triamcinolone acetonide require expensive manufacturing facilities and have thin profit margins, making them vulnerable to supply disruptions. When one or two manufacturers face issues, the remaining producers cannot quickly scale up to cover the gap.

Contributing factors include: manufacturer discontinuations (Eugia dropped out entirely), increased demand for corticosteroid injections as the U.S. population ages and arthritis rates climb, manufacturing compliance challenges at some facilities, and concentrated supply among a small number of producers.

How Does This Shortage Affect Patients?

For most patients, the Kenalog shortage means:

Your pharmacy may not have the injection in stock, even if you've been getting it there for years

Your doctor's office may have limited or no in-office supply

You may experience delays in receiving your injection, potentially leading to increased pain or inflammation

Your prescriber may need to switch you to a different corticosteroid temporarily

Patients with arthritis, autoimmune disorders, and chronic skin conditions who rely on regular Kenalog injections are among the most affected. If you use Kenalog for severe allergy season treatment ("allergy shots"), the shortage can leave you vulnerable during peak pollen times.

What Should Patients Do Right Now?

Contact your prescriber: Inform them of the shortage situation. They may have in-office supply or can switch you to an equivalent alternative like Depo-Medrol.

Use medfinder to check local pharmacy availability: medfinder calls pharmacies near you to find which ones can fill your prescription, saving you hours of calling.

Ask about specialty or hospital pharmacies: These may have access to allocated stock not available at retail chains.

Discuss alternatives: Ask your prescriber about Depo-Medrol, Celestone, or other corticosteroid options if Kenalog remains unavailable.

When Will the Kenalog Shortage Be Resolved?

There is no confirmed full-resolution date. Viatris has estimated a late-June 2026 release date for back-ordered vials. Some improvement in availability may occur as manufacturers work through back orders. However, Eugia's exit from this market is permanent, meaning the overall supply base for generic triamcinolone acetonide injection has permanently shrunk.

Need help finding Kenalog near you right now? Use medfinder to check pharmacies in your area, or read our tips guide: How to Find Kenalog In Stock Near You.

Frequently Asked Questions

Yes. As of 2025–2026, triamcinolone acetonide injectable suspension (Kenalog) remains on the ASHP active drug shortage list, with multiple manufacturers — including Eugia (discontinued), Hikma, Viatris, Teva, Long Grove, and Amneal — all simultaneously affected.

Viatris has estimated a late-June 2026 release date for back-ordered vial sizes. No other manufacturers have provided specific resolution dates as of early 2026. Eugia's exit is permanent, so the long-term supply base for generic triamcinolone acetonide injection has been permanently reduced.

Yes. Generic triamcinolone acetonide injectable suspension (40 mg/mL) is available and is the most common form used. However, the same shortage affecting brand Kenalog also affects generics, since most generic manufacturers are experiencing the shortage simultaneously.

Kenalog is sometimes used as a systemic corticosteroid injection for severe allergic conditions, not as a traditional allergen immunotherapy shot. If your doctor has been giving you Kenalog for allergy-related inflammation, the shortage may require switching to an alternative like Depo-Medrol or Celestone during peak allergy season.

The simultaneous shortage across multiple manufacturers reflects the fragility of the generic injectable drug market. Thin profit margins, expensive manufacturing requirements, and concentrated production among a small number of suppliers mean that when one producer exits (like Eugia did) or faces a back-order, the remaining producers cannot quickly compensate — especially when demand is also rising.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards

Patients searching for Kenalog also looked for:

32,136 have already found their meds with Medfinder.

Start your search today.

32K+
5-star ratingTrusted by 32,136 Happy Patients
      What med are you looking for?
⊙  Find Your Meds
99% success rate
Fast turnaround time
Never call another pharmacy

Need this medication?